As we delve deep into countless medical journals to uncover the latest on Integrative Medicine’s approach to kidney health, we are always reminded of the value of your time. Our commitment remains steadfast in curating and succinctly summarizing these vital studies for you. Welcome to the September Research and News.
Nutrition in Kidney Health
Could Magnesium Help Protect the Arteries in CKD?
This study examined the relationship between serum magnesium and coronary artery calcification (CAC) in 2,017 participants with stage 2–4 chronic kidney disease from the CRIC Study.
Higher magnesium levels were associated with substantially less severe coronary calcification at baseline.
After adjustment for demographic, clinical, and mineral metabolism factors, each 1 mg/dL higher serum magnesium was associated with 43% lower odds of having severe CAC.
However, among the 1,044 participants with repeat coronary calcium scans, magnesium levels were not significantly associated with progression of calcification over time.
Why is this important?
Vascular calcification is a major contributor to the exceptionally high cardiovascular risk seen in CKD, and magnesium has increasingly been proposed as a potential inhibitor of the calcification process.
This large CKD cohort strengthens the association between higher magnesium levels and lower vascular calcification burden, but importantly, it does not establish that increasing magnesium will prevent calcification from progressing.
Interventional studies are needed before magnesium supplementation can be recommended specifically for this purpose.
Could a Low-Carbohydrate Diet Help Prevent Chronic Kidney Disease?
This real-world study compared 11,077 adults participating in a telehealth nutrition program emphasizing individualized carbohydrate reduction with 11,077 matched adults receiving usual care over five years.
Participation in the low-carbohydrate intervention was associated with a 36% lower risk of developing CKD, a 43% lower risk of progressing to stage 3 or higher CKD, and a 62% lower risk of reaching stage 4 or higher.
Importantly, the intervention was not associated with increased rates of kidney stones, metabolic acidosis, diabetic ketoacidosis, or gout.
Why is this important?
Type 2 diabetes and obesity are major drivers of CKD, making metabolic health an important target for kidney disease prevention.
These findings suggest that an individualized, carbohydrate-restricted dietary intervention delivered through telehealth may provide a scalable approach to reducing CKD risk while addressing underlying metabolic disease.
However, because this was an observational retrospective study rather than a randomized clinical trial, it demonstrates an association and cannot prove that the low-carbohydrate intervention itself caused the reduction in CKD risk.
Gut-Kidney Connection
CKD May Change the Gut to Absorb More Phosphate
This experimental study provides new insight into the gut-kidney connection in phosphate balance. Normally, the kidneys and intestines work together to maintain phosphate homeostasis, with much of intestinal phosphate absorption occurring passively between intestinal cells through tight junctions.
Researchers found that simply changing dietary phosphate intake did not significantly alter this paracellular absorption pathway. In a mouse model of CKD, however, intestinal phosphate handling changed substantially: active phosphate transport failed to appropriately decrease despite hyperphosphatemia, while passive paracellular phosphate absorption actually increased.
The intestinal tight-junction proteins claudin-3 and claudin-7 were also disrupted. Importantly, the uremic toxin p-cresol increased phosphate permeability in human intestinal cells, suggesting that toxins accumulating as kidney function declines may directly alter the intestinal barrier.
Why is this important?
Phosphate imbalance in CKD is usually viewed primarily as a consequence of the kidneys losing their ability to excrete phosphate. This study suggests the gut may become an active contributor to the problem.
Uremic toxins produced or modified through the gut microbiome may disrupt the intestinal barrier and increase phosphate absorption, creating a potentially harmful gut-kidney feedback loop: declining kidney function increases uremic toxins, these toxins alter intestinal permeability, and the gut may then allow greater phosphate entry into the circulation.
Although these findings are preclinical, they identify the intestinal barrier and gut-derived uremic toxins as intriguing new targets for controlling phosphate burden in CKD.
Pharmaceuticals and Kidney Health
Antibiotic-Associated Kidney Injury in Children May Not Be Just About Crystals
This multicenter retrospective study examined acute kidney injury (AKI) and urinary drug crystals in 227 children treated for Mycoplasma pneumoniae infection, focusing on the fluoroquinolone tosufloxacin (TFLX).
Children already taking TFLX at their initial visit had a higher prevalence of AKI than those not receiving the drug (10% vs. 2%).
However, among children newly started on TFLX, AKI occurred in 2.6% and was not significantly more frequent than in controls. Gastrointestinal symptoms were strongly associated with AKI, occurring in 70% of children who developed AKI compared with 11% without AKI.
Although urinary drug crystals were common during TFLX treatment, they occurred at similar rates in children with and without AKI, suggesting that crystalluria alone does not explain the kidney injury.
Why is this important?
Drug crystals in the urine can raise concern for crystal-induced kidney injury, but this study shows that their presence does not necessarily mean they are causing AKI.
The strong association between gastrointestinal symptoms and AKI suggests that factors such as volume depletion may also contribute.
Clinicians using tosufloxacin should monitor kidney function particularly closely in children who develop vomiting, diarrhea, poor intake, or other gastrointestinal symptoms rather than relying on crystalluria alone as a marker of kidney injury.
Join us to end the kidney disease epidemic
Genetics and Epigenetics
Genetics May Help Explain Why Some People With Type 1 Diabetes Develop Kidney Disease
This study examined whether genetic risk for reduced kidney function and albuminuria in the general population also predicts kidney outcomes in people with type 1 diabetes.
Researchers analyzed 1,304 participants from the long-running DCCT/EDIC study who were followed for a median of 35 years.
A polygenic risk score associated with higher eGFR predicted better kidney function and an 18% lower risk of developing eGFR below 60 mL/min/1.73 m².
Separately, a genetic score for albuminuria predicted a higher risk of developing albuminuria. These associations persisted regardless of whether participants had received intensive or conventional glucose-lowering therapy, suggesting that inherited kidney risk operates independently of glycemic control.
Why is this important?
Not everyone with type 1 diabetes develops kidney disease, even with similar levels of glycemic control, and genetics may help explain some of this variability.
Interestingly, the genetic factors associated with declining eGFR appear to differ from those associated with albuminuria, suggesting that these two manifestations of diabetic kidney disease may have partly distinct biological pathways.
As genetic risk assessment improves, polygenic scores could potentially help identify people with diabetes who are particularly susceptible to kidney disease and may benefit from earlier, more individualized preventive strategies.
Review article of the month
The Gut–Kidney Connection: New to Conventional Nephrology, Familiar Territory for Integrative Medicine
This perspective reviews the rapidly expanding science of the gut–kidney–vascular axis and highlights a striking gap between biological evidence and its adoption into conventional nephrology.
In CKD, reduced clearance of gut-derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate, along with dietary changes, medications, and altered intestinal transit, can reshape the microbiome and contribute to inflammation, endothelial dysfunction, fibrosis, hypertension, and cardiovascular disease.
Other microbial metabolites, including TMAO and short-chain fatty acids, further demonstrate how closely intestinal, kidney, and vascular health are connected.
Yet the authors conclude that microbiome testing and microbiome-targeted therapies are not ready for routine conventional clinical practice because studies have not yet demonstrated sufficient reproducibility or improvements in hard kidney and cardiovascular outcomes.
Interestingly, many of the underlying concepts are not new to functional and integrative medicine, where nutrition, dietary fiber, gut health, microbial balance, and the downstream effects of microbial metabolites have long been incorporated into patient care.
The emerging science of the gut–kidney axis therefore represents an area where conventional nephrology may increasingly converge with principles already emphasized in integrative care.
Importantly, however, evidence that specific microbiome-directed interventions can slow CKD progression remains limited, and better clinical trials are still needed to determine which approaches actually improve outcomes.
Join here to receive FREE monthly updates on the latest research in Integrative Nephrology and tips on managing kidney disease straight to your inbox.
We would love to hear your feedback. Let us know what you think of these educational materials and if you would like us to focus on specific topics. Please email us at info@inkidney.com.
